UniProt P43403 · PDB · AlphaFold · Substrate: pEY · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Futibatinib | 46.1% | 53.9% | 98.48 | 0.718 |
| 2 | Ruxolitinib | 11.7% | 88.3% | 98.25 | 0.592 |
| 3 | Canertinib | 11.2% | 88.8% | 96.49 | 0.671 |
| 4 | Vemurafenib | 10.5% | 89.5% | 96.49 | 0.598 |
| 5 | Mobocertinib | 9.5% | 90.5% | 97.22 | 0.757 |
| 6 | Repotrectinib | 9.5% | 90.5% | 84.21 | 0.608 |
| 7 | Crizotinib | 9.3% | 90.7% | 91.39 | 0.581 |
| 8 | Erdafitinib | 7.1% | 92.9% | 95.71 | 0.737 |
| 9 | Neratinib | 6.8% | 93.2% | 93.18 | 0.597 |
| 10 | Asciminib | 6.3% | 93.7% | 100.00 | 0.602 |
| 11 | Lenvatinib | 6.2% | 93.8% | 97.74 | 0.726 |
| 12 | Capmatinib | 6.0% | 94.0% | 99.75 | 0.582 |
| 13 | Upadacitinib | 5.8% | 94.2% | 97.98 | 0.663 |
| 14 | Regorafenib | 5.4% | 94.6% | 95.99 | 0.719 |
| 15 | Dacomitinib | 5.4% | 94.6% | 97.99 | 0.664 |
| 16 | Pirtobrutinib | 4.9% | 95.1% | 99.49 | 0.656 |
| 17 | Tivozanib | 4.9% | 95.1% | 92.42 | 0.673 |
| 18 | Tenalisib | 4.6% | 95.4% | 97.98 | 0.702 |
| 19 | Entrectinib | 4.6% | 95.4% | 93.69 | 0.671 |
| 20 | Ceritinib | 4.5% | 95.5% | 95.44 | 0.618 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.14
- Epithelial log2(TPM+1): 0.33
- Fold change: -0.19
- Status: No significant change
Selectivity landscape vs inhibition on ZAP70
Each point is one of the 92 approved drugs; color = inhibition % on ZAP70.
Mutation lollipop
Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.
Variants (1)
Mutation × cancer associations
| Mutation | Cancer | Organ | Source |
|---|---|---|---|
| Y319F | chronic_lymphocytic_leukemia | Blood/Lymphatic System | ref |
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…